Overview

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

Status:
RECRUITING
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and Safety of Xiangjurupining Capsule in the treatment of Hyperplasia of Mammary Glands(stagnation of liver-qi and phlegm).
Phase:
PHASE3
Details
Lead Sponsor:
Tasly Pharmaceutical Group Co., Ltd